Alvotech (ALVO) reported $586M in revenue for fiscal 2025, +19.7% year on year. That ranks #2120 by revenue among 2853 SEC filers and #205 in Healthcare. Net income was $27.9M, a net margin of 4.8%. Revenue has grown 54.5% a year on average since 2020 ($66.6M then). The fiscal 2025 balance sheet shows $1.5B in total assets, $172M in cash and $1.3B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractsWithCustomers | $586M | +19.7% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeProfitLossFromOperatingActivities | $78.2M | +12.3% | FY20252025-12-31 |
| Net incomeProfitLoss | $27.9M | +$260M | FY20252025-12-31 |
| Operating cash flowCashFlowsFromUsedInOperatingActivities | −$50.2M | +$187M | FY20252025-12-31 |
| Capital expenditurePurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | $64.5M | +20.1% | FY20252025-12-31 |
| Total assetsAssets | $1.5B | +21.8% | FY20252025-12-31 |
| Shareholders' equityEquity | −$284M | +$128M | FY20252025-12-31 |
| CashCashAndCashEquivalents | $172M | +235.1% | FY20252025-12-31 |
| Long-term debtLongtermBorrowings | $1.3B | +21.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Figures are reported under IFRS, in US dollars.
Profile
- Legal name
- Alvotech
- Ticker
- ALVO
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0001898416
Filings
- 20-FMar 31, 2026Open filing →
- 20-FMar 27, 2025Open filing →
- 20-FMar 20, 2024Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Transmedics GroupTMDX | $605M | $190M |
| Ufp TechnologiesUFPT | $603M | $68.3M |
| Catalyst PharmaceuticalsCPRX | $589M | $214M |
| AlvotechALVO | $586M | $27.9M |
| BioventusBVS | $568M | $22.7M |
| Organogenesis HoldingsORGO | $564M | $37.0M |
| HUTCHMED (China)HCM | $549M | $457M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Alvotech — Key figures |url=https://companiesranked.com/en/company/alvotech |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Alvotech — Key figures. CompaniesRanked. https://companiesranked.com/en/company/alvotechBibTeX
@misc{companiesranked-en-company-alvotech-2026,
author = {{CompaniesRanked}},
title = {{Alvotech — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/alvotech}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001898416-26-000004 · March 31, 2026
{{cite web |title=Alvotech — Key figures — 20-F (0001898416-26-000004) |url=https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-31}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.